Evidence map›Paper›PMID 40498279›Full record

ArticleAdvances in therapy2025

Comorbid Depression and Anxiety Risk in Older Individuals with Geographic Atrophy: A US Claims Data Analysis.

Lisa J Faia, Jessica Ackert, Rachelle Rodriguez, Alyshah Abdul Sultan, Colleen Garey, Rachel E Teneralli, Rose Ong

Abstract read
In one paragraph

Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Visual Function Assessment in Geographic Atrophy: A Review.Clinical & experimental ophthalmology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lisa J FaiaAssociated Retinal Consultants, Royal Oak, MI, USA.
Jessica AckertJohnson & Johnson, Raritan, NJ, USA.
Rachelle RodriguezJohnson & Johnson, Raritan, NJ, USA.
Alyshah Abdul SultanJohnson & Johnson, Raritan, NJ, USA.
Colleen GareyPanalgo, Boston, MA, USA.
Rachel E TeneralliJohnson & Johnson, Raritan, NJ, USA.
Rose OngGlobal Epidemiology, Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company, Gewerbestrasse 16, 4123, Allschwil, Switzerland. cong3@its.jnj.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGeographic atrophy (GA), an advanced stage of nonexudative age-related macular degeneration (AMD), is associated with progressive central vision loss and blindness. While the association between GA and impaired vision-related quality of life has been established, understanding of the co-occurrence of anxiety and depression in individuals with GA is limited.

methodsWe conducted a retrospective, noninterventional, cohort study analyzing data from three large US databases (Optum's de-identified Clinformatics

resultsThe Clinformatics

conclusionThis study found a higher risk for comorbid depression or anxiety in patients with GA versus propensity score-matched controls. Risk was greatest among those with bilateral GA with subfoveal involvement. These findings highlight the important mental health burden experienced by patients with GA.

Indexed as

AnxietyDepressionGeographic AtrophyAgedAged, 80 and overComorbidityDatabases, FactualFemaleHumansMaleMiddle AgedRetrospective StudiesUnited StatesAge-related macular degenerationAnxietyBlindnessDepressionGeographic atrophyMental healthVisual impairment

Identifiers

PMID40498279
PMCPMC12313719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.